Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Other Accumulated Expenses (2020 - 2025)

Historic Other Accumulated Expenses for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to $116166.0.

  • Inhibikase Therapeutics' Other Accumulated Expenses rose 79016.09% to $116166.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $116166.0, marking a year-over-year increase of 79016.09%. This contributed to the annual value of $81000.0 for FY2024, which is 2121.93% down from last year.
  • Per Inhibikase Therapeutics' latest filing, its Other Accumulated Expenses stood at $116166.0 for Q3 2025, which was up 79016.09% from $74316.0 recorded in Q2 2025.
  • Inhibikase Therapeutics' 5-year Other Accumulated Expenses high stood at $3.1 million for Q3 2022, and its period low was $3322.0 during Q1 2021.
  • For the 5-year period, Inhibikase Therapeutics' Other Accumulated Expenses averaged around $622383.5, with its median value being $25561.0 (2024).
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 2656217.23% in 2022, then plummeted by 9960.0% in 2024.
  • Inhibikase Therapeutics' Other Accumulated Expenses (Quarter) stood at $5127.0 in 2021, then soared by 93.49% to $9920.0 in 2022, then soared by 936.46% to $102817.0 in 2023, then dropped by 21.22% to $81000.0 in 2024, then surged by 43.41% to $116166.0 in 2025.
  • Its Other Accumulated Expenses stands at $116166.0 for Q3 2025, versus $74316.0 for Q2 2025 and $127703.0 for Q1 2025.